On June 6, 2025, the European Medicines Agency's (EMA) safety committee (PRAC) concluded its review, linking Novo Nordisk's popular weight-loss drug Wegovy to a possible increased risk of developing non-arteritic anterior ischemic optic neuropathy (NAION). This rare eye condition may cause vision loss.
The findings from the EMA's review raise significant safety concerns for patients using Wegovy. This development could lead to increased regulatory scrutiny, potential label changes, and impact patient and physician confidence in the drug.
This regulatory action follows earlier scrutiny of Ozempic for a similar potential connection to eye disease. Novo Nordisk will need to address these safety concerns to maintain the drug's market standing and ensure patient trust.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.